Against the backdrop of deepening innovation in industry chain finance, the Class B Asset Express platform officially announced on August 6, 2026, that its asset financing service pilot scope will expand for the first time to the biomedical industry chain. This move marks the extension of Class B Asset Express from traditional manufacturing and new energy sectors to the high-value-added, long-cycle biomedical industry, offering a new pathway to solve financing challenges for pharmaceutical enterprises.
Prominent Financing Pain Points in the Biomedical Industry Chain
The biomedical industry is characterized by high R&D investment, long cycles, and slow payment collection. According to industry data, an innovative drug takes an average of 10 to 15 years from R&D to market launch, with R&D investment often reaching billions of yuan. Pharmaceutical enterprises generally face long payment cycles from core hospitals, slow medical insurance reimbursements, and severe accumulation of accounts receivable. Small and medium-sized biotech enterprises, in particular, often cannot meet their funding needs through traditional bank financing channels due to a lack of fixed asset collateral.
"Our company's R&D investment exceeded 300 million yuan last year, but the accounts receivable turnover days reached 280 days. A large amount of capital is tied up in the drug distribution process, severely impacting the advancement of our subsequent pipelines," said the CFO of a biomedical enterprise in Suzhou. This predicament is not an isolated case in the biomedical industry but a widespread structural challenge.
Class B Asset Express Innovative Model: Credit Penetration and Phased Rights Confirmation
Addressing the specificities of the biomedical industry chain, the innovative financing service launched by the Class B Asset Express platform revolves around three core mechanisms:
- Core Enterprise Credit Penetration: Leveraging the credit of core enterprises such as large pharmaceutical groups and Grade-A tertiary hospitals, blockchain technology enables multi-level credit circulation, allowing upstream small and medium-sized pharmaceutical enterprises to obtain financing against receivables from core enterprises without additional collateral.
- Drug Approval Pledge Financing: Incorporating intellectual property such as drug registration certificates and patent authorizations into the scope of financeable assets, with value assessment conducted by third-party professional evaluation agencies, opening new financing channels for R&D-oriented pharmaceutical enterprises.
- Phased Rights Confirmation Mechanism: Tailored to the long R&D cycle of pharmaceuticals, R&D projects are broken down by milestone nodes. Partial rights confirmation can be achieved upon completion of each node, enabling phased capital recovery during the R&D process.
"Traditional financing models often require enterprises to provide complete sales contracts or invoices, but accounts receivable for biomedical enterprises are often formed across multiple stages such as drug distribution and hospital payments, with highly fragmented documentation," said the product head of Class B Asset Express. "By connecting with pharmaceutical distribution platforms and hospital information systems, we achieve automatic capture and cross-verification of transaction data, significantly improving financing approval efficiency."
First Batch of Pilots Covers Three Major Industry Clusters
It is reported that the Class B Asset Express biomedical industry chain financing pilot will first be implemented in three major biomedical industry clusters: the Yangtze River Delta (Shanghai, Suzhou, Hangzhou), the Beijing-Tianjin-Hebei region (Beijing, Tianjin, Shijiazhuang), and the Guangdong-Hong Kong-Macao Greater Bay Area (Guangzhou, Shenzhen). The first batch of cooperating core enterprises includes 5 large pharmaceutical groups and 12 hospitals, expected to cover over 200 small and medium-sized biomedical enterprises within the year, releasing over 50 billion yuan in liquidity.
In terms of risk control, the platform has introduced a pharmaceutical industry expert think tank for evaluation and established a multi-dimensional dynamic rating model covering drug market potential, R&D progress, and policy risks. Meanwhile, the platform cooperates with multiple insurance companies to provide credit insurance coverage for receivables financing, further reducing financing risks.
Industry Interpretation: Industry Chain Finance Enters the Era of Refined Operations
Industry analysts point out that the extension of Class B Asset Express to the biomedical industry chain reflects the evolution of industry chain financial services from generic products to vertical industry deep cultivation. As a strategic emerging industry strongly supported by the state, the biomedical industry has highly specialized and customized financing needs that are difficult to meet with traditional standardized financing products.
"The difficulty of pharmaceutical industry chain financing lies not only in credit assessment but also in a deep understanding of specialized areas such as drug distribution, medical insurance settlement, and R&D progress," said a chief pharmaceutical industry analyst at a securities firm. "By introducing a pharmaceutical expert evaluation mechanism and a phased rights confirmation model, Class B Asset Express is essentially building a financing service system that better understands the industry, which is of great significance for improving the capital turnover efficiency of the biomedical industry."
From a policy perspective, the state has continuously encouraged financial institutions to increase support for the biomedical industry in recent years. In early 2026, the General Office of the State Council issued the "Several Opinions on Promoting High-Quality Development of the Pharmaceutical Industry," explicitly proposing to "innovate financial service models for the pharmaceutical industry chain and encourage the development of pledge financing for accounts receivable and intellectual property." The pilot expansion of Class B Asset Express is a positive response to this policy direction.
Future Outlook: From Biomedicine to More Vertical Fields
The Class B Asset Express platform stated that the successful experience of the biomedical industry chain financing pilot will provide a reference template for subsequent expansion into more vertical industries. Currently, the platform is already studying the replication of similar models to industries with long cycles and high investment characteristics, such as integrated circuits and high-end equipment manufacturing.
"We are building an intelligent risk control system based on industry knowledge graphs, achieving precise matching of financing services through deep deconstruction of different industry chains," revealed the technical head of Class B Asset Express. "In the future, enterprises will only need to submit basic transaction data, and the system will automatically generate a financing plan, truly realizing 'one-click financing.'"
As the pilot scope of Class B Asset Express continues to expand and its service model innovates, its role in revitalizing enterprises' existing assets and accelerating capital turnover will become more prominent. For biomedical enterprises, the implementation of this service undoubtedly provides strong financial support for alleviating capital pressure and accelerating the R&D process.
